Ontology highlight
ABSTRACT:
SUBMITTER: Shiseki M
PROVIDER: S-EPMC5608785 | biostudies-literature | 2017 Oct
REPOSITORIES: biostudies-literature
Shiseki Masayuki M Yoshida Chikashi C Takezako Naoki N Ohwada Akira A Kumagai Takashi T Nishiwaki Kaichi K Horikoshi Akira A Fukuda Tetsuya T Takano Hina H Kouzai Yasuji Y Tanaka Junji J Morita Satoshi S Sakamoto Junichi J Sakamaki Hisashi H Inokuchi Koiti K
International journal of clinical oncology 20170526 5
<h4>Background</h4>With the introduction of imatinib, a first-generation tyrosine kinase inhibitor (TKI) to inhibit BCR-ABL1 kinase, the outcome of chronic-phase chronic myeloid leukemia (CP-CML) has improved dramatically. However, only a small proportion of CP-CML patients subsequently achieve a deep molecular response (DMR) with imatinib. Dasatinib, a second-generation TKI, is more potent than imatinib in the inhibition of BCR-ABL1 tyrosine kinase in vitro and more effective in CP-CML patients ...[more]